Tangye, 2020 - Google Patents
Genetic susceptibility to EBV infection: insights from inborn errors of immunityTangye, 2020
- Document ID
- 5832938125288781412
- Author
- Tangye S
- Publication year
- Publication venue
- Human genetics
External Links
Snippet
Epstein–Barr virus (EBV) is a ubiquitous human pathogen, infecting> 90% of the adult population. In the vast majority of healthy individuals, infection with EBV runs a relatively benign course. However, EBV is by no means a benign pathogen. Indeed, apart from being …
- 230000036039 immunity 0 title abstract description 36
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tangye | Genetic susceptibility to EBV infection: insights from inborn errors of immunity | |
| Tangye et al. | Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection | |
| Latour et al. | Signaling pathways involved in the T‐cell‐mediated immunity against Epstein‐Barr virus: Lessons from genetic diseases | |
| Palendira et al. | Primary immunodeficiencies and the control of Epstein–Barr virus infection | |
| Williams et al. | Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers | |
| Kim et al. | Human cytomegalovirus requires epidermal growth factor receptor signaling to enter and initiate the early steps in the establishment of latency in CD34+ human progenitor cells | |
| Kang et al. | Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus | |
| McNamara et al. | Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation | |
| Phares et al. | CD4 T cells promote CD8 T cell immunity at the priming and effector site during viral encephalitis | |
| Wu et al. | Human cytomegalovirus-induced NKG2Chi CD57hi natural killer cells are effectors dependent on humoral antiviral immunity | |
| Severa et al. | EBV stimulates TLR‐and autophagy‐dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape | |
| Chijioke et al. | NK Cell influence on the Outcome of Primary epstein–Barr virus infection | |
| Palendira et al. | Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP | |
| Snow et al. | Epstein-Barr virus: evasive maneuvers in the development of PTLD | |
| Lilleri et al. | Human cytomegalovirus-specific memory CD8+ and CD4+ T cell differentiation after primary infection | |
| Navarro | Expanding role of cytomegalovirus as a human pathogen | |
| Smets et al. | Epstein–Barr virus‐related lymphoproliferation in children after liver transplant: Role of immunity, diagnosis, and management | |
| Dell’Oste et al. | Tuning the orchestra: HCMV vs. innate immunity | |
| Li et al. | Immunotherapy of murine retrovirus-induced acquired immunodeficiency by CD4 T regulatory cell depletion and PD-1 blockade | |
| Shi et al. | The role of innate immunity in natural elite controllers of HIV-1 infection | |
| Mohan et al. | Current understanding of HIV-1 and T-cell adaptive immunity: progress to date | |
| Williams et al. | Induction of the lytic cycle sensitizes Epstein-Barr virus-infected B cells to NK cell killing that is counteracted by virus-mediated NK cell evasion mechanisms in the late lytic cycle | |
| Raftery et al. | Inhibition of CD1 antigen presentation by human cytomegalovirus | |
| Jones et al. | Varicella-zoster virus downregulates programmed death ligand 1 and major histocompatibility complex class I in human brain vascular adventitial fibroblasts, perineurial cells, and lung fibroblasts | |
| Shen et al. | Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells |